source
- Biotech firms increase product launches as capital markets improveA growing number of biotech companies are bringing new medicines to market, a trend analysts link to improving capital markets. While the majority of approved drugs still come from large pharmaceu…
- Novartis stops ALS TREM2 stabilizer after Phase 2 miss, marking fourth trial setback in a monthNovartis has halted development of its TREM2 stabilizer VHB937, also known as lifonebart, for amyotrophic lateral sclerosis after the drug failed to meet either the primary or secondary endpoints i…